ProShares Ultra Nasdaq Biotechnology
BIB NASDAQ
ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. This leveraged ProShares ETF seeks a return that is 2x the return of its underlying benchmark (target) for a sin...
Hover to inspectDrag to measure a move← → to step through days
- Fund size
- 152M as of Feb 2020
- Expense ratio
- 0.95% per year
- Dividend yield
- 0.21% Quarterly
- Volatility · 1Y
- 43.8% High Risk
- Beta
- 1.46 vs the market
- 52-week range
- 64.22126.13
How BIB has paid off
Price return over every period, and total return with dividends reinvested, set against its benchmark.
Return by period
Price · to Oct 12Total return vs benchmark
Total Market US Cap Weighted 1200 IndexOver 1 year, BIB returned +69.8% with dividends reinvested — +16.0 pts ahead of its benchmark.
How bumpy is the ride?
Return only means something next to the risk taken to earn it. Volatility, drawdowns and market sensitivity over 1 year.
Volatility
Annualized · 1YA typical year sees the price swing about ±44% around its trend.
Drawdown from peak
How far below its previous high the price has been Deepest fall −16.9% on Mar 27, 2026 — 31 days after the previous high
More than 5% below a high 51% of the time.
Risk vs reward
1YOver 1 year, BIB delivered more return, with more risk than its benchmark.
Market sensitivity
BetaA beta of 1.46 means BIB has moved more than the market.
Trend & momentum
Where the price sits against its moving averages, and how stretched the recent move is.
Price vs moving averages
Uptrend- 12-day average110.22 −1.3%
- 26-day average111.45 −2.4%
- 50-day average110.01 −1.1%
- 200-day average94.05 +15.7%
The price is above 1 of 4 averages. The 50-day average is above the 200-day, a sign of a rising longer-term trend.
Relative strength (RSI)
NeutralRSI compares recent gains with recent losses on a 0–100 scale. Above 70 a move is often considered stretched, below 30 washed out.
Technical indicators describe past prices. They are not a forecast.
Inside the fund
Health Care · Leveraged x2 — tracking the Nasdaq Biotechnology Index®.
- Assets under management152MUSD
- Expense ratio0.95%per year
- Holdings290
- Risk score8.3High
Launched April 2010. Listed options available. Fund data as of Feb 27, 2020.
What it pays you
Cash distributions over the last twelve months, and how they have grown.
About 2 USD a year for every 1,000 USD invested at today's price.
- Per share
- 0.22
- Frequency
- Quarterly
- Last paid
- Sep 23, 2026
Last 12 months
0.22 USD / shareWhere BIB shows up
Curated themes and indices that hold BIB. Open one to see it in context, or test the whole theme in a portfolio.
About ProShares Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. This leveraged ProShares ETF seeks a return that is 2x the return of its underlying benchmark (target) for a single day, as measured from one NAV calculation to the next.
- Featured in 1 curated theme
- 290 holdings
- Ticker
- BIB
- Exchange
- NASDAQ
- ISIN
- US74347R2141
- CUSIP
- 74347R214
- Currency
- U.S. Dollar (USD)
- Country
- USA
- Sector
- Health Care
- Industry
- Leveraged x2
- Benchmark
- Total Market US Cap Weighted 1200 Index
All key statistics
Details
Shareas of Oct 12, 2026
Dataas of Feb 27, 2020
Put BIB to the test
See how it would change the return and the risk of a portfolio, with virtual money, before a single real dollar moves.
Data for information only, not investment advice. Past performance does not guarantee future results.